Critical role of the high mobility group A proteins in hematological malignancies

Abstract

The high mobility group A (HMGA) protein family is composed of three non-histone chromatin remodeling proteins that act as architectural transcriptional factors. Indeed, although HMGA proteins lack transcriptional activity per se, they bind the minor groove of DNA at AT-rich sequences, and, interacting with the transcription machinery, are able to modify chromatin modeling, thus regulating the expression of several genes. HMGA proteins have been deeply involved in embryogenesis process, and a large volume of studies has pointed out their key role in human cancer.Here, we review the studies on the role of the HMGA proteins in human hematological malignancies: they are overexpressed in most of the cases and their expression correlates with a reduced survival. In some cases, such as in acute lymphoblastic leukemia and acute myelogenous leukemia, HMGA2 gene rearrangements have been also described. Finally, recent studies evidence a synergism between HMGA and EZH2 in diffuse B-cell lymphomas, suggesting an innovative therapy for this disease based on the inhibition of the function of both these proteins.

Small Extracellular Vesicles and Their Involvement in Cancer Resistance: An Up-to-Date Review

“…Simply put, the suppression of E-cadherin expression and the increased expression of N-cadherin and vimentin suggest that tumor cells can uptake HMGA1 regulatory exosomes and undergo an immensely active epithelial–mesenchymal transition (EMT) [ 40 ]. This observation supports the well-known data, which show that HMGA1, an oncofetal protein, is responsible for the aggressive properties of many cancer cells, leading to poor prognoses for patients in the course of the disease [ 73 , 74 , 75 ]. Therefore, the regulation of this axis may potentially be used in the therapy of cancer patients.…”

Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment

“…The findings on how high mobility group protein 2 (HMGA2) modulates mutagenic responses are important to consider, as this information could influence the effects of chemotherapeutic agents. In HNSCC, HMGA2 is associated with enhanced specific chemosensitivity to the topoisomerase inhibitor II (doxorubicin) ( De Martino et al, 2022 ). HPV-16-induced malignancies are a separate category of HNC, they are more commonly observed in the oropharynx, and since HPV-infected epithelial cells are very sensitive to chemotherapy, this category has a better chance of cure ( Zhou et al, 2022 ).…”

High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential

“…Enhancer of zeste-homolog 2 (EZH2), as an enzymatic subunit of PRC2, plays a cancer promoting role by catalyzing the methylation of histone H3 lysine 27 within PRC2 and regulating the G2/M transition of the cell cycle. HMGA1 combines with the promoter region of EZH2 to promote its transcription to enhance the proliferation and migration of B-cell lymphomas 115 , 116 . MiR-26 has been proven to be a multiple tumour suppressor; it does not control IL-6-related inflammation and tumour promoting activity through transcription inhibition but downregulates the production of IL-6 through HMGA1 and MALT1 silencing-induced NF-κB inhibition 117 .…”